Viz.ai, a leader in AI-powered disease detection and care coordination, has announced a multi-year partnership with pharmaceutical companies Sanofi and Regeneron to develop and evaluate an artificial intelligence solution for chronic obstructive pulmonary disease (COPD) management.
The collaboration will focus on deploying the Viz COPD module, an AI-powered care acceleration solution that analyzes electronic health record (EHR) data to improve detection and management of high-risk COPD patients. This technology builds upon Viz.ai's established presence in over 1,700 hospitals and health systems, with more than 60,000 healthcare providers already using the platform.
"At Sanofi, we're excited to collaborate with Viz.ai to further address unmet needs in COPD care by leveraging AI," said Paul Rowe, MD, ATSF & Head of Medical, Specialty Care at Sanofi. "With this collaboration, we will study the impact of the Viz COPD module, a streamlined AI-enabled EHR workflow to improve access to care and ultimately patient outcomes in COPD, a disease that remains underprioritized, underfunded and undertreated in comparison to other noncommunicable diseases."
COPD represents a significant global health challenge, affecting an estimated 392 million people worldwide and ranking as the fourth leading cause of death globally. The disease places substantial strain on healthcare systems, with utilization and costs increasing as symptoms progress. Many COPD patients fail to receive optimal treatment due to improper risk assessment, poor care coordination, inadequate monitoring, and administrative barriers to therapy.
The new Viz COPD module will employ natural language processing to screen EHR data and triage patients according to established clinical guidelines, identifying high-risk individuals who require follow-up care. The partners aim to maximize impact particularly for patients who would benefit most from improved follow-up and care coordination.
"This collaboration with Sanofi and Regeneron is a major step forward in our mission to expand AI-driven care coordination across disease areas with critical unmet needs, such as COPD," said Chris Mansi, MD, CEO and co-founder of Viz.ai. "Our approach aims to empower healthcare providers to deliver data-driven, guideline-directed care that meaningfully impacts patient outcomes. We look forward to collaborating with Sanofi and Regeneron to harness AI to accelerate advancements in disease management and improve patient access to care."
Viz.ai's existing platform, Viz.ai One®, is an intelligent care coordination solution that identifies patients with suspected disease, provides critical decision support at the point of care, and helps optimize care pathways to improve outcomes. The company reports that its solutions are backed by real-world clinical evidence and deliver significant value to patients, providers, and pharmaceutical and medical device companies.
Click here for the original news story.